Publications

Filters: Keyword is Survival Rate  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Survival Rate
Owzar, Kouros, Zhiguo Li, Nancy Cox, and Sin-Ho Jung. "Power and sample size calculations for SNP association studies with censored time-to-event outcomes." Genet Epidemiol 36, no. 6 (2012): 538-48.
Ganti, Apar Kishor, Xiaofei Wang, Thomas E. Stinchcombe, Yinpeng Wang, Jeffrey Bradley, Harvey J. Cohen, Karen Kelly, Rebecca Paulus, Suresh S. Ramalingam, Everett E. Vokes et al. "Clinical prognostic model for older patients with advanced non-small cell lung cancer." J Geriatr Oncol 10, no. 4 (2019): 555-559.
Samsky, Marc D., Chetan B. Patel, Ashleigh Owen, Phillip J. Schulte, Jacob Jentzer, Paul B. Rosenberg, Michael G Felker, Carmelo A. Milano, Adrian F. Hernandez, and Joseph G. Rogers. "Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
Jung, Sin-Ho, and Shein-Chung Chow. "On sample size calculation for comparing survival curves under general hypothesis testing." J Biopharm Stat 22, no. 3 (2012): 485-95.
Wong, Kin Yau, Cheng Fan, Maki Tanioka, Joel S. Parker, Andrew B. Nobel, Donglin Zeng, Dan-Yu Lin, and Charles M. Perou. "I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms." Genome Biol 20, no. 1 (2019): 52.
Geng, Yuan, Hao Helen Zhang, and Wenbin Lu. "On optimal treatment regimes selection for mean survival time." Stat Med 34, no. 7 (2015): 1169-84.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Mentz, Robert J., Phillip J. Schulte, Jerome L. Fleg, Mona Fiuzat, William E. Kraus, Ileana L. Piña, Steven J. Keteyian, Dalane W. Kitzman, David J. Whellan, Stephen J. Ellis et al. "Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION)." Am Heart J 165, no. 2 (2013): 193-9.
Secord, Angeles Alvarez, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, Chris J Brady, Heather A. Lankes, Herbert I. Hurwitz et al. "Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Vock, David M., Anastasios A. Tsiatis, Marie Davidian, Eric B. Laber, Wayne M. Tsuang, Ashley Finlen C Copeland, and Scott M. Palmer. "Assessing the causal effect of organ transplantation on the distribution of residual lifetime." Biometrics 69, no. 4 (2013): 820-9.
Rashid, Naim U., Xianlu L. Peng, Chong Jin, Richard A. Moffitt, Keith E. Volmar, Brian A. Belt, Roheena Z. Panni, Timothy M. Nywening, Silvia G. Herrera, Kristin J. Moore et al. "Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer." Clin Cancer Res 26, no. 1 (2020): 82-92.
Kwak, Minjung, and Sin-Ho Jung. "Optimal two-stage log-rank test for randomized phase II clinical trials." J Biopharm Stat 27, no. 4 (2017): 639-658.